Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats.
The effects of various i.v. doses (2.5, 5, 10 and 15 mg/kg) of the highly efficient inhibitor of multiple enkephalin-degrading enzymes, Kelatorphan, were evaluated on the vocalization threshold to paw pressure in normal rats and in rats with Freund's adjuvant-induced arthritis. In normal rats, Kelatorphan at doses as low as 2.5 mg/kg i.v. at which the enkephalinase inhibitor acetorphan was ineffective, produced potent antinociceptive effects, comparable to that induced by 1 mg/kg i.v. morphine. In contrast, for the higher doses used (5, 10, 15 mg/kg i.v.), the effects of Kelatorphan were not more pronounced than that of acetorphan. Unlike acetorphan, Kelatorphan was found to be much more effective in arthritic than in normal rats in raising the vocalization threshold, even at the lower concentration, 2.5 mg/kg i.v.: 244% in arthritic vs 144% in normal rats. The effects of Kelatorphan were prevented by naloxone at the dose of 0.5 mg/kg i.v. The enhanced potency of Kelatorphan is discussed in relation with the increase in peptidase-sensitive dynorphin fragments in arthritic rats.
Kayser
V
V
Unité de Recherches de Physiopharmacologie du Système Nerveux, U 161 INSERM, Paris, France.
Fournie-Zaluski
M C
MC
Guilbaud
G
G
Roques
B P
BP
D000818:Animals; D001168:Arthritis / Q000150:complications*; D001169:Arthritis, Experimental / Q000150:complications*; D004151:Dipeptides / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004745:Enkephalins / Q000378:metabolism / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D051381:Rats; D011919:Rats, Inbred Strains
D004151:Dipeptides; D004745:Enkephalins; D004791:Enzyme Inhibitors; D009270:Naloxone; C042591:kelatorphan